Anti-angiogenic properties of myo-inositol trispyrophosphate in ovo and growth reduction of implanted glioma.
We investigate here the anti-angiogenic properties of the synthetic compound myo-inositol trispyrophosphate (ITPP). By increasing oxy-haemoglobin dissociation, ITPP has the potential to counteract the effects of hypoxia, a critical regulator of angiogenesis and cancer progression. ITPP inhibited angiogenesis of the chorioallantoic membrane (CAM), as analyzed with an original program dedicated to automated quantification of angiogenesis in this model. ITPP also markedly reduced tumor progression and angiogenesis in an experimental model of U87 glioma cell nodules grafted onto the CAM. These results point out the potential of ITPP for the development of a new class of anti-angiogenic and anti-cancer compounds.
Sihn
Gabin
G
Laboratoire de Pathologie Vasculaire et Endocrinologie Rénale, Inserm U36, Collège de France, 11, place Marcelin Berthelot, 75005 Paris, France. g.sihn@mdc-berlin.de
Walter
Thomas
T
Klein
Jean-Claude
JC
Queguiner
Isabelle
I
Iwao
Hiroshi
H
Nicolau
Claude
C
Lehn
Jean-Marie
JM
Corvol
Pierre
P
Gasc
Jean-Marie
JM
D000482:Allantois / Q000098:blood supply / Q000187:drug effects; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D045744:Cell Line, Tumor; D002642:Chick Embryo; D002823:Chorion / Q000098:blood supply / Q000187:drug effects; D005910:Glioma / Q000098:blood supply / Q000188:drug therapy; D006801:Humans; D007295:Inositol Phosphates / Q000494:pharmacology*; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D014183:Transplantation, Heterologous
D020533:Angiogenesis Inhibitors; D007295:Inositol Phosphates; C516441:inositol trispyrophosphate